Septerna (NASDAQ:SEPN) Shares Up 12.2% – Still a Buy?

Septerna, Inc. (NASDAQ:SEPN)’s stock price rose 12.2% during mid-day trading on Thursday . The company traded as high as $17.62 and last traded at $17.45. Approximately 106,955 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 197,869 shares. The stock had previously closed at $15.55.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SEPN shares. TD Cowen initiated coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Wells Fargo & Company initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $43.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 price objective for the company.

Septerna Stock Down 4.5 %

The business’s 50 day moving average price is $21.70.

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Septerna during the 4th quarter valued at approximately $185,000. Rhumbline Advisers acquired a new position in shares of Septerna in the 4th quarter valued at $458,000. Finally, New York State Common Retirement Fund purchased a new position in Septerna in the 4th quarter worth $32,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.